Kisqali Femara Co-Pack 600 mg-2.5 mg Dose and Subvenite

• Generic Name: letrozole / ribociclib
• Dosage Forms: kit
• Other Brand Names: Kisqali Femara Co-Pack 200 mg-25 mg Dose, Kisqali Femara Co-Pack 400 mg-25 mg Dose, Kisqali Femara Co-Pack 600 mg-25 mg Dose

Letrozole lowers estrogen levels, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.

Ribociclib interferes with the growth and spread of cancer cells in the body.

Kisqali Femara Co-Pack 600 mg-2.5 mg Dose are used together in combination to treat HR-positive, HER2-negative breast cancer in women.

Kisqali Femara Co-Pack 600 mg-2.5 mg Dose is used when the cancer has spread to other parts of the body (metastatic).

Kisqali Femara Co-Pack 600 mg-2.5 mg Dose are two different medicines that are packaged together. Letrozole tablets are yellow and ribociclib tablets are violet.

Kisqali Femara Co-Pack 600 mg-2.5 mg Dose may also be used for purposes not listed in this medication guide.

• Generic Name: lamotrigine
• Dosage Forms: tablet
• Other Brand Names: Lamictal, Lamictal ODT, Lamictal XR, Subvenite, Lamictal, Lamictal ODT, Lamictal XR, Lamictal CD, LaMICtal Starter Kit, LaMICtal ODT Patient Titration Kit, LaMICtal XR Patient Titration Kit, LamoTRIgine Starter Kit, Subvenite Starter Kit

Subvenite is an anti-epileptic medication, also called an anticonvulsant.

Subvenite is used alone or with other medications to treat epileptic seizures in adults and children. This medicine is also used to delay mood episodes in adults with bipolar disorder (manic depression).

Immediate-release Subvenite can be used in children as young as 2 years old when it is given as part of a combination of seizure medications. However, this form should not be used as a single medication in a child or teenager who is younger than 16 years old.

Extended-release Subvenite is for use only in adults and children who are at least 13 years old.

Subvenite may also be used for purposes not listed in this medication guide.